Pulmonary embolism and/or deep vein thrombosis in COVID-19 patients.

Recruiting

• Conditions: COVID19Deep vein Thrombosis; U07.1; I26.9; COVID-19, virus identified; Pulmonary embolism without mention of acute cor pulmonale

• Registration Number: DRKS00021604
• Lead Sponsor: Zollernalb Klinikum Balingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

•written informed consent
•naso-pharyngeal swap SARS-CoV-2 PCR positiv or clinical high suspicion of COVID-19 infection
•Elevated D-Dimer concentration of > 10µg/l*age (starting at 50 years, in younger patients the cut-off is 500 µg/l) and dyspnoea and/or a O2-saturation <92%
•indication for in-patient treatment

Exclusion Criteria

•Age < 18 years
•Allergy to contrast agent
•Renal insufficiency with a GFR < 40 (ml/min/1,73 m2)
•Pregnancy
•Pulmonary embolism and/or deep vein thrombosis in the last six months
•Hyperthyreosis

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary embolism and/or deep vein thrombosis in COVID-19 patients

Secondary Outcome Measures

Name	Time	Method
•60 days in-hospital mortality due to thromboembolism<br>•60 days all-cause mortality<br>•Need for treatment in the ICU<br>•Need for ventilation therapy<br>•Duration of hospitalisation<br>•Positiv predictive value of Wells Score in COVID-19 patients